(UroToday.com) The first session of the Advanced Prostate Cancer Consensus Conference (APCCC) 2021 which was hosted virtually in the context of the COVID-19 pandemic focused on the management of patients with newly diagnosed metastatic hormone-sensitive prostate cancer. Previous presentations in this session have discussed a variety of treatment options for patients in this disease space: in addition to an androgen deprivation therapy (ADT) backbone, androgen receptor signaling inhibitors, taxane-based chemotherapy, and local prostate-directed therapy may be considered. Dr. Himisha Beltran concluded this session by discussing whether molecular markers can inform treatment decisions in this disease space.